The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib,
which will be marketed as Rasonque. The drug is the first therapy targeting one
of the disease's key molecular pathogenic mechanisms. A late-stage trial
published in May showed Daraxonrasib nearly doubled typical survival in an
aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with
chemotherapy, the current standard of care.
